In silico analysis showed that the designed peptides are readily bound to the Wnt- and DKK-binding interfaces of LRP6, and may be considered as possible therapeutic modalities for inhibiting Wnt-mediated cancer progression and invasion. The gene discussed is LRP6; the disease is cancer.